Showing 4421-4430 of 5771 results for "".
- Amazon Unveils Pharmacy Offering, Hitting Shares of Drug Retailershttps://modernod.com/news/amazon-unveils-pharmacy-offering-hitting-shares-of-drug-retailers/2478569/Amazon.com announced Tuesday the launch of Amazon Pharmacy, allowing customers in the US to complete an entire pharmacy transaction on their desktop or mobile device through the Amazon app. The move sent shares in other drug retailers down, with Walgreens Boots falling over 11%, CVS Health slippi
- Alcon Canada Introduces AcrySof IQ Vivity Presbyopia-Correcting IOLhttps://modernod.com/news/alcon-canada-introduces-acrysof-iq-vivity-presbyopia-correcting-iol/2478568/Alcon has announced the Canadian launch of AcrySof IQ Vivity presbyopia-correcting IOL. AcrySof IQ Vivity uses a non-diffractive design called X-WAVE technology and provides an extended range of vision and reduced dependency on glasses following cataract surgery.
- IRIS Registry Reveals Insights into Eye Disease Prevention and Treatmenthttps://modernod.com/news/worlds-largest-specialty-clinical-data-registry-reveals-insights-into-eye-disease-prevention-and-treatment/2478566/The IRIS Registry powered a number of big data studies this year, many of which were presented at AAO 2020 Virtual, the 124th annual meeting of the American Academy of Ophthalmology. The research findings are now available to view on demand. “With a growing pool of aggregated d
- Horizon: New Data Build on Growing Evidence Supporting Tepezza Efficacy in Thyroid Eye Disease (TED)https://modernod.com/news/horizon-new-data-build-on-growing-evidence-supporting-tepezza-efficacy-in-thyroid-eye-disease-ted/2478563/Horizon Therapeutics announced new Tepezza (teprotumumab-trbw) data presented at the American Academy of Ophthalmology Annual Meeting (
- Kodiak Sciences Completes Enrollment of Phase 2b/3 Pivotal Study of KSI-301 in Patients with Wet AMDhttps://modernod.com/news/kodiak-sciences-completes-enrollment-of-phase-2b-3-pivotal-study-of-ksi-301-in-patients-with-wet-amd/2478561/Kodiak Sciences announced that recruitment has concluded in its DAZZLE pivotal study of KSI-301, Kodiak’s anti-VEGF antibody biopolymer conjugate, in patients with wet age-related macular degeneration (AMD). DAZZLE was planned to enroll 550 treatment-naïve patients worldwide; the target enr
- B+L: Investigational In Vitro Data Indicates Complete Inactivation Of SARS-CoV-2 With Lumify and Besivance Eye Dropshttps://modernod.com/news/bausch-health-announces-investigational-in-vitro-data-indicating-complete-inactivation-of-sars-cov-2-with-lumify-and-besivance-eye-drops/2478558/Bausch Health Companies and Bausch + Lomb announced the results of new investigational in vitro data showing that two benzalkonium chloride (BAK) preserved eye drops, Lumify (brimonidine tartrate ophthalmic solution 0.025%) redness reliever eye drops and Besivance (besifloxacin ophthalmic
- EyePoint Pharmaceuticals Presents Positive Data of Yutiq and Dexycu in Four Poster Sessions at AAO 2020https://modernod.com/news/eyepoint-pharmaceuticals-presents-positive-data-of-yutiq-and-dexycu-in-four-poster-sessions-at-aao-2020/2478559/EyePoint Pharmaceuticals announced that positive data for Yutiq and Dexycu were featured in four presentations at the recent American Academy of Ophthalmology (AAO) 2020 Virtual Annual Meeting. Data presented included: Statistically significant effi
- Late-Breaking 12-Month Data of Investigational RPGR Gene Therapy Shows Statistically Significant and Continued Vision Improvement in Patients with XLRPhttps://modernod.com/news/late-breaking-12-month-data-of-investigational-rpgr-gene-therapy-shows-statistically-significant-and-continued-vision-improvement-in-patients-with-xlrp/2478557/The Janssen Pharmaceutical Companies of Johnson & Johnson announced new 12-month data from the ongoing phase 1/2 trial (
- Moderna Says mRNA COVID-19 Vaccine 94.5% Effectivehttps://modernod.com/news/moderna-says-mrna-covid-19-vaccine-94-5-effective/2478555/Moderna announced Monday that in the first interim analysis of the phase 3 COVE study, its experimental COVID-19 vaccine mRNA-1273 demonstrated efficacy of 94.5%. The company noted that the analysis was based on 95 cases of coronavirus infection, of which 90 cases were observed in the placebo gro
- iSTAR Medical’s Glaucoma Device MINIject Shows Positive One-Year Results in European Trialhttps://modernod.com/news/istar-medicals-glaucoma-device-miniject-shows-positive-one-year-results-in-european-trial/2478552/iSTAR Medical announced positive 1-year results from the European STAR-II clinical trial of its micro-invasive glaucoma surgery (MIGS) device, MINIject. The results have been presented at the virtual American Academy of Ophthalmology (AAO) annual meeting, held November 13-15 2020. Po